A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia (Mycoplasma hyopneumoniae) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs by Panagiotis D. Tassis et al.
RESEARCH ARTICLE Open Access
A randomized controlled study on the
efficacy of a novel combination vaccine
against enzootic pneumonia (Mycoplasma
hyopneumoniae) and porcine Circovirus
type 2 (PCV2) in the presence of strong
maternally derived PCV2 immunity in pigs
Panagiotis D. Tassis1*, Ioannis Tsakmakidis1, Vassileios G. Papatsiros2, Dimitrios Koulialis1, Tom Nell3,
Georgia Brellou4 and Eleni D. Tzika1
Abstract
Background: Mycoplasma hyopneumoniae (M. hyo) and Porcine Circovirus Type 2 (PCV2) are major pathogens that
cause significant health problems in swine worldwide. Maternal derived immunity (MDI) has been suggested as
a significant immediate defence factor for newborn piglets and may interfere with piglet’s vaccination-induced
immunity. The study aimed to assess the efficacy of a novel combination vaccine (consisting of PCV2 subunits and
inactivated M. hyo strain J), against PCV2 and M. hyo natural infection [Porcilis® PCV M Hyo (MSD Animal Health,
Boxmeer, the Netherlands)], in the presence of strong maternally derived PCV2 immunity (antibody titre averaged
11.08 log2), under field conditions. The study was performed according to a controlled, randomized and blinded
design in a Greek swine unit with Enzootic Pneumonia (EP) and subclinical PCV2 infection. In total, 600 healthy
three-week-old suckling piglets were allocated randomly, either to treatment (vaccinated with the test product)
or control group (injected with sterile buffered saline).
Results: Vaccination significantly reduced the severity of lung lesions at slaughter (lesions of cranio-ventral pulmonary
consolidation) (P < 0.001). The overall mean lung lesion score (LLS) was 9.6 in the vaccinated group and 12.2 in
controls. The level of PCV2 viraemia was significantly reduced in vaccinated pigs. Furthermore, 25 g higher average
daily weight gain (ADWG) was observed during the finishing phase (P < 0.001) and 18 g greater ADWG overall
(P < 0.001).
Conclusions: Results of LLS, PCV2 viremia and ADWG support the test product’s efficacy in the face of strong
maternally derived PCV2 immunity.
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Background
Mycoplasma hyopneumoniae (M. hyo) and Porcine
Circovirus Type 2 (PCV-2) are two major pathogens of
ubiquitous nature that cause critical health disorders
in swine worldwide. M. hyo is part of the aetiology of
a chronic insidious bronchopneumonia, also described
as enzootic pneumonia (EP) which causes severe eco-
nomic losses in the global pig industry [1]. Other bac-
terial agents usually coexist in cases of EP along with
M. hyo. The EP clinical manifestations include a dry,
non-productive cough, variable reduction of feed
intake and growth retardation [2]. Moreover, viral
pathogens such as Porcine Reproductive and Respira-
tory Syndrome virus (PRRSv) and PCV2 have been
suggested as agents that contribute further in convert-
ing EP into the more complex Porcine Respiratory
Disease Complex [2, 3].
PCV-2, with four genotypes documented up to today
(PCV2a, PCV2b, PCV2c, PCV2d-mPCV2b), has been
etiologically associated with certain Porcine Circovirus
Diseases (PCVD) [4]. Those include disorders such as
PCV2 - Systemic Disease (PCV2-SD) (formerly known
as postweaning multisystemic wasting syndrome) which
is characterised by growth retardation - wasting, an-
aemia, possible respiratory problems and diarrhoea, as
well as lymphocyte depletion and immune suppression.
Moreover, PCV2 is present in the aetiology of porcine
dermatitis and nephropathy syndrome, and clinical
manifestations of pneumonia, reproductive failure or
intestinal disorders [5–7]. However, subclinical PCV2
infection occurs frequently and although clinically
“silent”, gradually results in significant economic losses
due to growth retardation [8].
Vaccination of piglets is the main control method
against clinical disease associated with M. hyo (eg.
more than 85% of US farms vaccinate against M. hyo)
[1, 3]. For almost a decade (since 2007), control of
PCVD has been also based on vaccination of sows and/
or piglets [3, 9]. Nevertheless, those two pathogens per-
sist, circulate and interact with other pathogens in the
host, making their clearance extremely difficult [7, 10].
The double edged sword case of maternal derived im-
munity (MDI) as a significant immediate defence factor
for newborn piglets and its possible interference on
piglet’s active immunity is a point of controversy. So far,
it seems that MDI [including cell-mediated (CMI) and
antibody-mediated immunity (AMI)] through colostrum
and milk may interfere to some extent with the induc-
tion of AMI and CMI responses in piglets after vaccin-
ation [11–13]. Previous studies suggested that high MDI
levels at the moment of vaccination could affect vaccine-
induced seroconversion [5, 14–17].
The objective of this study was to assess the efficacy of
a ready-to-use combination vaccine [Porcilis® PCV M
Hyo (MSD Animal Health, Boxmeer, The Netherlands)]
against concurrent clinical M. hyo and subclinical PCV2
infection under field conditions, in the face of strong




Farm selection was performed after pre-trial scoring of
lung lesions according to the method of Goodwin and
Whittlestone [18], along with PCV2 serology. Pre-trial
results suggested an existing EP with typical lung lesions
(cranio-ventral pulmonary consolidation) in >90% of
tested lungs, along with high maternally derived PCV2
antibody titres at three weeks of piglets’ age. In addition,
PCV2 antibodies were also measured after the 16th week
of age and further increased until the pigs’ slaughter age
(22nd week). Thus, the trial farm was considered as clin-
ically affected with EP and subclinically affected by
PCV-2. The farrow-to-finish farm was in Northern
Greece with approximately 800 sows under production.
The test product is a new combination vaccine that
induces immunity against PCV2 and M. hyo, and con-
sists of Baculovirus expressed PCV2 subunits and inacti-
vated M hyo strain J in Emunade adjuvant (Porcilis®
PCV M Hyo, MSD Animal Health, Boxmeer, The
Netherlands). The test product evaluated in this study is
registered in the European Union [19].
The efficacy evaluation of the test product was set as a
placebo controlled, randomized and blinded study.
Piglets were assigned individually (within litters) to the
treatment groups. At admission, the animals were ear
tagged as they came to hand and were allocated with the
use of a computer-generated randomisation list (only
known to EDT) to one of the two treatment groups,
until the required number of piglets had been reached.
In total, 600 three-week-old suckling piglets from three
production batches (equal number of male and female)
were allocated randomly to one of two groups (day 0 of
the trial - December 2010). Each group consisted of 300
animals at day 0 of the study. Only clinically healthy pig-
lets were included in the study. Diseased piglets, runts
and animals with abnormalities (e.g. hernia) were ex-
cluded. On day 0 of the trial, treatment group pigs were
vaccinated intramuscularly (neck area) with 2 ml of the
combination vaccine and control group animals were
injected in a similar way with Unisol (sterile phosphate
buffered saline and sucrose). In total, 285 pigs from the
treatment group and 277 control animals reached the
end of the study.
Allocation sequence was concealed until administration
of the test product or Unisol to the trial animals. Enroll-
ment, administration of products to the trial animals and
assignment to each group was performed by two members
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(namely, P. Tassis and E. Tzika) of the research group.
Animals of both groups were commingled throughout the
study and they received feed and water according to the
farm’s schedule. Although the test and control product
were visibly different (only relevant at the time of adminis-
tration), the study was blinded. After vaccination, all farm
and laboratory, or other personnel involved, either carry-
ing out observations or measurements, could not identify
the vaccination status of the pigs, as it was not possible to
differentiate piglets by treatment without unblinding the
ear tag number. A detailed study flow diagram is pre-
sented in Fig. 1. Furthermore, the sows from which study
piglets originated had been routinely vaccinated against
major pathogens (PCV-2, Aujeszky’s disease virus, PRRSv,
porcine parvovirus, Erysipelothrix rhusiopathiae, atrophic
rhinitis and Escherichia coli).
Recorded parameters
Each individual pig was weighed at admission, at transfer
to the finishing unit (week five post-vaccination) and
shortly before the first animals of each batch were trans-
ferred to the slaughterhouse [week 20 post-vaccination
(end of study)]. Medication was recorded and pigs that
died during the study were examined post-mortem to
establish the cause of death based on gross lesions, with
the exception of cases where the cause was clear and
unrelated to PCV2, or M. hyo infection, or vaccination
(e.g. cases of severe post-traumatic lameness). The lungs
of trial animals were examined individually by the same
pathologist at slaughter to score the severity of typical
M. hyo lesions according to the same methodology as in
the pre-trial screening [18]. The lesions of cranio-ventral
pulmonary consolidation (expressed as lung lesions
score - LLS) of each tested lung was the addition of the
proportion of each lobe surface with signs of typical M.
hyo associated inflammation (consolidated, grey to pur-
ple coloured), multiplied with the weighting factor of
each lobe [20]. The LLS score ranged from 0 to 55 at
maximum. Also pleuritis lesions were scored as Grade 0
- no pleuritis lesions, Grade 1 - topical adhesions (spots)
and Grade 2 - larger adhesions. Due to a minor data
recording error, weighing data from 282 animals (out of
285) from the treatment group and 274 control pigs (out
of 277) were analyzed at slaughter. Similarly, pleuritic
lesions were evaluated from 279 vaccinated and 269 con-
trol pigs. Technical issues during lung extraction at
slaughter, led to the evaluation of LLS data from a total
of 266 treated animals and 257 controls.
The LLS, average daily weight gain (ADWG) in the
finishing period and PCV2 viraemia results, were
considered primary parameters for the assessment of
vaccine efficacy. Additionally, overall ADWG (from
vaccination until slaughter), mortality, morbidity (refer-
ring to the number of pigs that received individual
medication) and the pleuritis lesions score, were also
evaluated as secondary parameters. All procedures dur-
ing this clinical study were carried out according to the
Guidelines on Good Clinical Practices [21] and the
Fig. 1 Study flow diagram
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animals were maintained in accordance with National
and European Animal Welfare Requirements [22].
Blood sampling and serology
Thirty-two piglets per vaccination group were bled for
serum samples every four weeks, starting from day 0. To
monitor field infections and to assess serological response
to vaccination, the sera were tested with PCV2 ELISA [23]
and M. hyo ELISA (Swine HerdChek M. Hyo IDEXX) as
per manufacturer instructions. The PCV2 titres were
expressed as the reciprocal of the serum dilution with a
calculated maximum extinction value of 50%. For calcula-
tion of the mean and standard deviation of antibody titres,
samples that were negative at the lowest dilution (<4) were
set at three. Similarly, samples that were positive at the
highest dilution (>14) were set at 15.
The M. hyo test results were expressed as sample to
positive (S/P) ratio and scored as ‘positive’, ‘inconclusive’
or ‘negative’. Based on serology, natural PCV2 infection
and relative seroconversion occurred during early finish-
ing (12–20 weeks post vaccination), thus PCV2 levels in
serum were measured by qPCR [23] during that period.
The qPCR results were expressed as log10 copies/μl
DNA extract. If the viral load was below the detection
limit of 2 log10 copies/μl DNA extract, the result was
considered negative and set at zero (0). The serum
samples taken on study week 20 were also tested for
antibodies to Actinobacillus pleuropneumoniae with
APP OMP ELISA [24], swine influenza virus (H1N1,
H1N2 and H3N2) with haemagglutination inhibition
tests and PRRSv with ELISA (IDEXX PRRS X3 Ab Test).
Statistical analysis
The pig was the statistical unit and the level of significance
was set at 0.05. Sample size calculation suggested that in-
clusion of approximately 300 piglets in each group had
80% power to detect a difference in means of 25 g a day
between groups, assuming that the common standard de-
viation was 100 g in a two group t-test with a 0.05 two-
sided significance level. The LLS were compared between
the vaccination groups using mixed model analysis of vari-
ance (ANOVA) with the lung lesions log transformed be-
fore analysis. Vaccination group was included as fixed
effect and the sow and production batch as random ef-
fects. The ADWG was compared between the vaccination
groups using a mixed model ANOVA. Vaccination group
and gender with their interaction were included as fixed
effects and sow and production batch as random effects.
The bodyweight at admission was included in the model
as a covariate. The proportions of pigs with pleuritis le-
sions (absent or present), as well as mortality and morbid-
ity were compared between groups by Cochran Mantel
Haenszel method with production batch as classification
variable. The mean individual qPCR results for PCV2




The ADWG in the vaccinated group significantly in-
creased by 25.3 g per day during the finishing period
(Mixed model ANOVA: P < 0.001). Moreover, ADWG
during the total study period was also significantly greater
by 18.0 g per day in vaccinated pigs than controls (Mixed
model ANOVA: P < 0.001). Results of ADWG are
presented in Table 1.
PCV2 viraemia
A total of 101 samples were tested by qPCR for PCV2
viral DNA. The mean viral load was significantly (Rank
Sum test: P = 0.0004) lower in the vaccinated pigs than
the controls. The results, expressed as the mean log10
DNA copies per μl DNA extract, are summarised in
Fig. 2. Presented data refer only to the period when re-
sults were above the detection limits.
Lung and pleuritis lesions score
The primary parameter of LLS was significantly re-
duced in the vaccinated group when compared with the
controls (Mixed model ANOVA P < 0.001). Table 2
summarizes results of LLS and pleuritis lesions among
groups. The LLS was further “separated” into four cat-
egories [i.e. score = 0 (absent), score= > 0–5 (mild),
score= > 5–10 (moderate), score > 10 (severe)]. The
evaluation of this distribution showed that more than
half of the control group cases were categorized in the
fourth category, while less than 40% of the vaccinated
group cases were in the same category (Fig. 3).
Insignificant differences in the proportion of animals
with pleuritis lesions were observed between the trial
groups (P = 0.0759). Representative findings of lung
and pleuritis lesions are presented in Fig. 4.
Mortality and morbidity
In total, 38 pigs (6.3%), 15 vaccinated and 23 controls,
died during the study. According to gross lesions that
were reported after necropsy, respiratory disease (fibrino-
necrotizing pleuropneumonia) was an important cause of
death, especially in the control group (12 cases), compared
Table 1 Mean average daily weight gain (standard error of the
mean) by vaccination group and period
Period Vaccinated group (g/day) Control group (g/day)
Nursery period 341 (5) 349 (5)
Finishing period 770a(8) 745b(8)
Overall 665c(6) 647d(6)
a,b,c,dMean values with different superscripts in the same row are significantly
different. Pairwise comparison (Mixed model ANOVA): ab: P < 0.0001, cd: P < 0.0001
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with only three cases in the vaccinated group. On the
other hand, gastrointestinal disease (enteritis) was the
cause of death in two cases from the vaccinated group
and five cases from the control group. The remaining
animals died of other causes (mainly post-traumatic).
Mortality between the groups was not statistically sig-
nificant (P = 0.1799).
Fifty two vaccinated animals and 54 control piglets re-
ceived individual medication, mostly for gastro-intestinal
(diarrhoea) or respiratory problems. The number of
treatments for respiratory signs (18) was lower than for
gastro-intestinal disease (25) in the vaccinated group,
while the opposite was observed in the control group
(28 v 25). Morbidity between groups was not statistically
significant (P = 0.8307).
Serology
At the beginning of the study (day 0), approximately
45% of piglets were seropositive for M hyo. Towards the
end of the study, the percentage of seropositive pigs
increased to 100% in the vaccinated group and approxi-
mately 75% in the controls (Fig. 5). On the day of
vaccination, PCV2 maternally derived antibody titre
averaged 11.2 log2 in the vaccinated group and 10.9 log2
in the control group (average 11.08 log2 for all trial ani-
mals), which is considered high [5]. The mean PCV2
antibody titres in both treatment groups increased be-
tween 12 and 20 weeks after vaccination (Fig. 6). The
maximum mean titre in the control group remained
below 8 log2, which is considered low. At the end of the
study, all pigs were seropositive for PRRSv and had
moderate to high antibody titres to the outer membrane
protein of Actinobacillus pleuropneumoniae. Low anti-
body titres were measured for swine influenza types
H1N1 and H2N3, while the titres against type H1N2
were all below the detection limit (4 log2).
Discussion
The current study demonstrates efficacy of the M hyo
and PCV2 combination vaccine in 3 week old piglets in
the presence of high PCV2 MDI level. Results of this
study are in agreement with previous findings regarding
the efficacy of the combination vaccine in the face of
average PCV2 MDI levels (9.38 log2) [25].
Definitive diagnosis of EP is based on the demonstra-
tion of typical lung lesions [3]. The mean LLS in this
study were significantly reduced in the vaccinated pigs,
indicating the test product’s efficacy against M. hyo. In
addition, lung lesions were also less severe in vaccinated
pigs as nearly two thirds of vaccinated animals had a
score < 10 compared to more than half of the controls
with a score > 10. This finding further supports the vac-
cine’s efficacy against EP.
Fig. 2 Mean log10 DNA copies PCV2 /per μl DNA extract, by vaccination group and weeks post-vaccination. Presented data refer only to the period
when results were above the detection limits
Table 2 Results of LLS and pleuritis lesions among trial groups
Lung lesions score (Mean score ± SD)
Vaccinated group
(n = 266)
Control group (n = 257)
9.6a ± 6.6 12.2b ± 7.8





No pleurisy lesions* 77% 70%
Topical lesions /spots 21% 25%
More extended lesions 3% 5%
a,b,Mean values with different superscripts in the same row are significantly different
Pairwise comparison (Mixed model ANOVA): ab: P < 0.0001
*Cochran Mantel Haenszel method: P = 0.0759
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Moreover, during the finishing period, vaccinated pigs
had a significantly better ADWG and the overall gain
was 18 g per day greater than in the control pigs. The
ADWG results were also in agreement with several pre-
vious studies with monovalent intramuscular M. hyo
vaccination in piglets [2, 26, 27]. Since serology results
suggested a subclinical PCV2 farm infection, alterations
of ADWG probably can also be attributed to some ex-
tent to the control of PCV-2. The reduced viraemia after
the 16th week in comparison with controls can be con-
sidered as the main factor that contributed to the PCV-
2-control-related improvement of ADWG.
The M. hyo serology results on Study day 0 suggest a
natural farm infection with M. hyo. Therefore, most
likely maternally derived M. hyo antibodies were
detected in suckling piglets on day 0, due to pathogen
circulation in breeding animals. Differences in antibody
titres among groups on Day 0, can be attributed to
natural M. hyo infection dynamics. Differences in M.
hyo circulation, and the consequent seroconversion in
sows, along with the effect of serum half-life of mater-
nally derived M. hyo antibodies, resulted in variation of
their relative levels in colostrum and blood of suckling
piglets. Furthermore, during the progress of the study,
seroconversion and relative differences in M. hyo anti-
body levels between groups were observed in the last
two samplings. Those differences were mainly attrib-
uted to the beneficial immune-boosting effect of
vaccination. Thus, a strong immune response was ob-
served in animals that received the test product and
counteracted natural M. hyo infection with significant
antibody production. On the contrary, control animals
had a weaker humoral response. Similar immune re-
sponse of piglets against natural M. hyo infection after
administration of the combination vaccine has been
previously reported [25].
Fig. 3 Distribution of lung lesion scores among value-range categories per group
Fig. 4 Representative findings of lung and pleuritis lesions in trial
animals. Figure a: lung has normal appearance. Figures b and c: purple
(b) and grey (c) consolidation located in cranial and middle lobes. In
Fig. c the caudal lobes are also affected. Figure d: lung shows intense
purple consolidation of the cranial, middle and caudal lobes. Figure e:
in ventral view of the previous lung (d), lesions of bronchopneumonia
are distributed in all lobes. Figure f: enzootic pneumonia complicated
with Actinobacillus pleuropneumoniae infection accompanied by localized
fibrous pleurisy (left caudal lobe). [a - c: Vaccinated group (Porcilis PCV M
Hyo)] [d - f: Control group (Unisol)]
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Previous studies suggest that PCV2 persists in swine
tissues and seroconversion has been shown in both sub-
clinical and PCV2-SD clinically affected pigs under field
conditions. In contrast, weaker immune responses have
been associated with PCV2-SD clinical cases [28–30].
The trial farm was a subclinical PCV2 infected farm and
a probable enhancement of PCV2 replication around the
12th week of age occurred possibly due to animal move-
ment and/or introduction of a different PCV2 genotype
[20, 31]. PCV2 serology results suggested an increased
antibody response in vaccinated pigs in comparison with
controls, throughout the course of the study. More
important, after the time of natural infection, the
humoral immune response of vaccinated animals was
greater than control pigs, thus demonstrating a strong
protective effect of the test product to a subclinical
PCV2infection. Furthermore, qPCR results provided
evidence that the mean PCV2 viral load was lower in
vaccinated pigs than in controls, while viral circulation
after PCV2 seroconversion was also reduced during the
period when the virus was detectable.
Maternal derived immunity transfer to piglets is very
important for the neonate’s immune response and sur-
vival during the first days of life. Moreover, it has been
suggested that MDI is a factor that may have a signifi-
cant impact on the success of vaccination under field
conditions [32]. In this subclinically infected PCV2 trial
farm, the level of maternally derived PCV2 antibodies
on the day of vaccination was high, thus a significant
negative interference with piglets immune priming could
be anticipated. However, our results do not support such
a negative MDI effect, considering that primary vaccine
Fig. 5 Percentage (%) of M. hyo ELISA positive samples, by vaccination group and weeks post-vaccination
Fig. 6 Mean log2 PCV2 antibody titres, by vaccination group and weeks post-vaccination
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efficacy parameters such as LLS, ADWG, viraemia were
all significantly improved/promoted in the vaccinated ver-
sus control animals.
Conclusions
According to the results of the present field study, vaccin-
ation with a ready to use PCV2/M hyo combination
vaccine of three-week-old piglets with high MDI was
effective against concurrent clinical M. hyo and subclinical
PCV-2 infection based on reduced LLS severity and PCV2
viraemia, as well as improved ADWG.
Abbreviations
ADWG: Average daily weight gain; AMI: Antibody-mediated immunity;
CMI: Cell-mediated immunity; EP: Enzootic pneumonia; LLS: lung lesion
score; M. hyo: Mycoplasma hyopneumoniae; MDI: Maternal derived immunity;
PCV2: Porcine circovirus type 2; PCV2-SD: PCV2 - Systemic disease;
PCVD: Porcine circovirus diseases; PRRSv: Porcine reproductive and
respiratory syndrome virus; SD: Standard deviation
Acknowledgements
The authors would like to acknowledge the support of the personnel of the
Laboratory of Pathology, School of Veterinary Medicine Aristotle University of
Thessaloniki, Greece, for lung lesion scoring and post mortem examinations.
Also, we would like to thank the personnel of the laboratories of MSD
Animal Health, Boxmeer, The Netherlands, for performing serological tests.
Funding
The test product and the control group solution for injection were supplied
by MSD Animal Health, Boxmeer, The Netherlands, who also funded the trial.
Availability of data and materials
All relevant data and materials are available in the main manuscript.
Authors’contributions
PDT, TN, EDT: Conception of protocol, trial interventions, data analysis and
interpretation, manuscript preparation. IT, VGP, DK: trial interventions, data
recording, manuscript corrections. GB: Pathological evaluation, interpretation of
results and data evaluation. All authors read and approved the final manuscript.
Competing interests
One of the authors (TN) is an employee of the funding body.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The trial has been approved by the Research Committee of the Aristotle
University of Thessaloniki, Greece (grant number 86788, to E. Tzika). Farm
manager has agreed in written consent to participate in the study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Farm Animals Clinic, School of Veterinary Medicine, Aristotle University of
Thessaloniki, St. Voutyra 11, 54627 Thessaloniki, Greece. 2Clinic of Medicine,
Faculty of Veterinary Science, University of Thessaly, P.O. Box 199Trikalon 224,
Karditsa, Greece. 3Animal Health, Clinical Study Team Biologicals, P.O. Box 31,
Boxmeer 5830 AA, the Netherlands. 4Laboratory of Pathology, School of
Veterinary Medicine, Aristotle University of Thessaloniki, University Campus,
54124 Thessaloniki, Greece.
Received: 24 August 2016 Accepted: 30 March 2017
References
1. Simionatto S, Marchioro SB, Maes D, Dellagostin OA. Mycoplasma
hyopneumoniae: from disease to vaccine development. Vet Microbiol.
2013;165:234–42.
2. Maes D, Segales J, Meyns T, Sibila M, Pieters M, Haesebrouck F. Control
of Mycoplasma hyopneumoniae infections in pigs. Vet Microbiol.
2008;126:297–309.
3. Thacker E, Minion F. (2012) Mycoplasmosis. In: Zimmerman J, Karriker L,
Ramirez A, Schwartz K, Stevenson G, editors. Diseases of swine. 10th ed.
Chichester: Wiley and Sons Inc; 2012. p. 779–788.
4. Franzo G, Cortey M, Olvera A, Novosel D, De Castro AMMG, Biagini P, et al.
Revisiting the taxonomical classification of porcine Circovirus type 2 (PCV-2):
still a real challenge. Virol J. 2015;12:131.
5. Fort M, Sibila M, Pérez-Martín E, Nofrarías M, Mateu E, Segalés J. One dose
of a porcine circovirus 2 (PCV-2) sub-unit vaccine administered to 3-week-
old conventional piglets elicits cell-mediated immunity and significantly
reduces PCV2 viremia in an experimental model. Vaccine. 2009;27:4031–7.
6. Segalés J. Porcine circovirus type 2 (PCV-2) infections: clinical signs,
pathology and laboratory diagnosis. Virus Res. 2012;164:10–9.
7. Kekarainen T, Segalés J. Porcine circovirus 2 immunology and viral
evolution. PHM. 2015;1:17.
8. Alarcon P, Rushton J, Nathues H, Wieland B. Economic efficiency analysis of
different strategies to control post-weaning multi-systemic wasting
syndrome and porcine circovirus type 2 subclinical infection in 3-weekly
batch system farms. Prev Vet Med. 2013;110:103–18.
9. Beach NM, Meng XJ. Efficacy and future prospects of commercially available
and experimental vaccines against porcine circovirus type 2 (PCV-2). Virus
Res. 2012;164:33–42.
10. Del Pozo Sancristan R. Treatment and control of Mycoplasma hyopneumoniae





otgb8s3KbqQJgXWGLQ7Qcg&cad=rja. Accessed 1 Apr 2017.
11. Bandrick M, Theis K, Molitor TW. Maternal immunity enhances Mycoplasma
hyopneumoniae vaccination induced cell-mediated immune responses in
piglets. BMC Vet Res. 2014;10:124.
12. Bandrick M, Ariza-Nieto C, Baidoo SK, Molitor TW. Colostral antibody-
mediated and cell-mediated immunity contributes to innate and antigen-
specific immunity in piglets. Dev Comp Immunol. 2014;43:114–20.
13. Martelli P, Saleri S, Ferrarini G, De Angelis E, Cavalli V, Benetti M, et al.
Impact of maternally derived immunity on piglets’ immune response and
protection against porcine circovirus type 2 (PCV-2) after vaccination against
PCV2 at different age. BMC Vet Res. 2016;12:77.
14. Fraile L, Sibila M, Nofrarías M, López-Jimenez R, Huerta E, Llorens A, et al.
Effect of sow and piglet porcine circovirus type 2 (PCV-2) vaccination on
piglet mortality, viraemia, antibody titre and production parameters. Vet
Microbiol. 2012;161:229–34.
15. Fraile L, Grau-Roma L, Sarasola P, Sinovas N, Nofrarías M, López-Jimenez R,
et al. Inactivated PCV2 one shot vaccine applied in 3-week-old piglets:
improvement of production parameters and interaction with maternally
derived immunity. Vaccine. 2012;30:1986–92.
16. Oh Y, Seo HW, Park C, Chae C. Comparison of sow and/or piglet vaccination
of 3 commercial porcine circovirus type 2 (PCV-2) single-dose vaccines on
pigs under experimental PCV2 challenge. Vet Microbiol. 2014;172:371–80.
17. Feng H, Segalés J, Fraile L, López-Soria S, Sibila M. Effect of high and low
levels of maternally derived antibodies on porcine circovirus type 2 (PCV-2)
infection dynamics and production parameters in PCV2 vaccinated pigs
under field conditions. Vaccine. 2016;34:3044–50.
18. Goodwin RFW, Whittlestone P. Enzootic pneumonia of pigs: immunisation
attempts inoculating M. Suipneumoniae antigen by various routes and with
different adjuvants. Brit Vet J. 1973;129:456–62.
19. EMA - European Medicines Agency Summary of opinion (initial authorisation) -




Tassis et al. BMC Veterinary Research  (2017) 13:91 Page 8 of 9
authorisation%2Fveterinary%2F003796%2FWC500172824.pdf&usg=AFQjCNE_
BXqRlhpiohL76tJi35WOxKF1uQ&sig2=syyvEBH39F1yCrV4Q9qbiQ&cad=rja.
Accessed 1 Apr 2017.
20. Segales J, Allan GM, Domingo M. Porcine circoviruses. In: Zimmerman J,
Karriker L, Ramirez A, Schwartz K, Stevenson G, editors. Diseases of swine.
10th ed. Chichester: Wiley and Sons Inc; 2012. p. 405–15.
21. EMEA - European Agency for the evaluation of Medicinal Products. Guidelines





jk53xkX86DxjmmQ&cad=rja. Accessed 1 Apr 2017.
22. FVE - Federation of Veterinarians of Europe. European Veterinary Ethics and




byTepVL4kr7muUjUWg&cad=rja. Accessed 1 Apr 2017.
23. Haake M, Palzer A, Weissenbacher-Lang C, Fachinger V, Eggen A,
Ritzmann M, et al. Influence of age on the effectiveness of PCV2
vaccination in piglets with high levels of maternally derived antibodies.
Vet Microbiol. 2014;168:272–80.
24. Van den Bosch H, Frey J. Interference of outer membrane protein PalA with
protective immunity against Actinobacillus pleuropneumoniae infection in
vaccinated pigs. Vaccine. 2003;21:3601–7.
25. Tzika ED, Tassis PD, Koulialis D, Papatsiros VG, Nell T, Brellou G, Tsakmakidis I.
Field efficacy study of a novel ready-to-use vaccine against mycoplasma
hyopneumoniae and porcine circovirus type 2 in a Greek farm. PHM. 2015;1:15.
26. Maes D, Deluyker H, Verdonck M, Castryck F, Miry C, Lein A, et al. Effect of
vaccination against Mycoplasma hyopneumoniae in pig herds with a
continuous production system. J Veterinary Med Ser B. 1998;45:495–505.
27. Maes D, Deluyker H, Verdonck M, Castryck F, Miry C, Vrijens B, et al. Effect of
vaccination against Mycoplasma hyopneumoniae in pig herds with an
all-in/all-out production system. Vaccine. 1999;17:1024–34.
28. Larochelle R, Magar R, D'allaire S. Comparative serologic and virologic study
of commercial swine herds with and without postweaning multisystemic
wasting syndrome. Can J Vet Res. 2003;67:114–20.
29. Meerts P, Misinzo G, Lefebvre D, Nielsen J, Bøtner A, Kristensen CS, et al.
Correlation between the presence of neutralizing antibodies against porcine
circovirus 2 (PCV-2) and protection against replication of the virus and
development of PCV-2-associated disease. BMC Vet Res. 2006;2:6.
30. Grau-Roma L, Hjulsager CK, Sibila M, Kristensen CS, Lopez-Soria S, Enøe C, et al.
Infection, excretion and seroconversion dynamics of porcine circovirus type 2
(PCV-2) in pigs from post-weaning multisystemic wasting syndrome (PMWS)
affected farms in Spain and Denmark. Vet Microbiol. 2009;135:272–82.
31. Rose N, Opriessnig T, Grasland B, Jestin A. Epidemiology and transmission of
porcine circovirus type 2 (PCV-2). Virus Res. 2012;164:78–89.
32. Maes D. Vaccination against Mycoplasma hyopneumoniae infection in pigs:
room for improvement. Vet J. 2014;200:214–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tassis et al. BMC Veterinary Research  (2017) 13:91 Page 9 of 9
